Literature DB >> 2317557

Evidence that several high-frequency human blood group antigens reside on phosphatidylinositol-linked erythrocyte membrane proteins.

M J Telen1, W F Rosse, C J Parker, M K Moulds, J J Moulds.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder associated with absence of expression of phosphatidylinositol (PI)-linked membrane proteins from circulating hematopoietic cells of multiple lineages. Recent work demonstrated that decay accelerating factor, one such PI-linked protein, bears the Cromer-related blood group antigens. This study demonstrated that other high incidence antigens, including Cartwright (Yta/Ytb), Holley-Gregory (Hy/Gya), John Milton Hagen (JMH), and Dombrock (Doa/Dob), are absent from the complement-sensitive (PNH III) erythrocytes of patients with PNH. The relatively normal, complement-insensitive erythrocytes from the same patients express these antigens normally. Therefore, these antigens most likely reside on PI-linked proteins absent from PNH III, but not PNH I, erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317557

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Investigation of Dombrock Blood Group Alleles and Genotypes among Saudi Blood Donors in Southwestern Saudi Arabia.

Authors:  Amr J Halawani; Abdullah S Mansor; Hamza M Assaggaf; Hibah A Almasmoum; Hisham I Abu-Tawil; Khalaf F Alsharif; Gasim Dobie; Mahmoud M Habibullah
Journal:  Genes (Basel)       Date:  2022-06-17       Impact factor: 4.141

2.  Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism.

Authors:  C F Bartels; T Zelinski; O Lockridge
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

Review 3.  Semaphorins: their dual role in regulating immune-mediated diseases.

Authors:  Zahava Vadasz; Elias Toubi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.